Vaxart Inc. (VXRT): Price and Financial Metrics


Vaxart Inc. (VXRT): $2.18

0.05 (+2.35%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add VXRT to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

VXRT POWR Grades

  • Value is the dimension where VXRT ranks best; there it ranks ahead of 35.32% of US stocks.
  • The strongest trend for VXRT is in Growth, which has been heading down over the past 177 days.
  • VXRT ranks lowest in Momentum; there it ranks in the 3rd percentile.

VXRT Stock Summary

  • VAXART INC's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than only 7.16% of US listed stocks.
  • With a price/sales ratio of 736.49, VAXART INC has a higher such ratio than 99.6% of stocks in our set.
  • As for revenue growth, note that VXRT's revenue has grown -71.03% over the past 12 months; that beats the revenue growth of only 2.16% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to VAXART INC, a group of peers worth examining would be DTIL, MRUS, LVTX, CRIS, and ADAP.
  • Visit VXRT's SEC page to see the company's official filings. To visit the company's web site, go to vaxart.com.

VXRT Valuation Summary

  • In comparison to the median Healthcare stock, VXRT's price/sales ratio is 15816.13% higher, now standing at 740.1.
  • VXRT's price/earnings ratio has moved down 4.9 over the prior 243 months.

Below are key valuation metrics over time for VXRT.

Stock Date P/S P/B P/E EV/EBIT
VXRT 2022-09-23 740.1 1.9 -2.9 -2.0
VXRT 2022-09-22 768.2 1.9 -3.0 -2.1
VXRT 2022-09-21 771.6 1.9 -3.0 -2.1
VXRT 2022-09-20 813.9 2.0 -3.1 -2.3
VXRT 2022-09-19 852.6 2.1 -3.3 -2.4
VXRT 2022-09-16 912.8 2.3 -3.5 -2.7

VXRT Growth Metrics

    Its 3 year revenue growth rate is now at -94.16%.
  • Its 5 year price growth rate is now at -77.99%.
  • Its 2 year cash and equivalents growth rate is now at 313.29%.
VXRT's revenue has moved down $1,291,000 over the prior 15 months.

The table below shows VXRT's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-06-30 0.359 -81.093 -92.878
2022-03-31 0.471 -68.353 -79.564
2021-12-31 0.892 -59.832 -70.47
2021-09-30 1.174 -54.784 -63.567
2021-06-30 1.239 -49.772 -54.069
2021-03-31 1.65 -37.134 -46.93

VXRT's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • VXRT has a Quality Grade of D, ranking ahead of 8.43% of graded US stocks.
  • VXRT's asset turnover comes in at 0.007 -- ranking 401st of 680 Pharmaceutical Products stocks.
  • ABEO, BCDA, and PCRX are the stocks whose asset turnover ratios are most correlated with VXRT.

The table below shows VXRT's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.007 1 -2.885
2021-03-31 0.011 1 -7.113
2020-12-31 0.038 1 81.691
2020-09-30 0.099 1 12.466
2020-06-30 0.159 1 19.968
2020-03-31 0.174 1 -81.273

VXRT Price Target

For more insight on analysts targets of VXRT, see our VXRT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $12.50 Average Broker Recommendation 1.5 (Moderate Buy)

VXRT Stock Price Chart Interactive Chart >

Price chart for VXRT

VXRT Price/Volume Stats

Current price $2.18 52-week high $8.13
Prev. close $2.13 52-week low $2.02
Day low $2.09 Volume 2,224,600
Day high $2.31 Avg. volume 2,651,783
50-day MA $3.24 Dividend yield N/A
200-day MA $4.24 Market Cap 275.78M

Vaxart Inc. (VXRT) Company Bio


Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines. Its products include Influenza, Norovirus and Respiratory Syncytial Virus. The company was founded in 2004 and is headquartered in South San Francisco, CA.


VXRT Latest News Stream


Event/Time News Detail
Loading, please wait...

VXRT Latest Social Stream


Loading social stream, please wait...

View Full VXRT Social Stream

Latest VXRT News From Around the Web

Below are the latest news stories about VAXART INC that investors may wish to consider to help them evaluate VXRT as an investment opportunity.

Vaxart to Present at the H.C. Wainwright 24th Annual Global Investment Conference

SOUTH SAN FRANCISCO, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Andrei Floroiu, President and Chief Executive Officer, Dr. Sean Tucker, Founder and Chief Scientific Officer, and Dr. James Cummings, Chief Medical Officer, will be presenting virtually at the H.C. Wainwright 24th Annual Global Investment Conference taking place September 12-14, 2022. The pre-recorded presentation will be available on the Company’s Events page, accessible here: https:

Yahoo | September 7, 2022

Analysts Offer Insights on Healthcare Companies: Mesoblast (MESO) and Vaxart (VXRT)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Mesoblast (MESO – Research Report) and Vaxart (VXRT – Research Report). Mesoblast (MESO) Maxim Group analyst Jason McCarthy maintained a Buy rating on Mesoblast yesterday and set a price target of $10.00. The company's shares closed last Thursday at $3.02. According to TipRanks.com, McCarthy has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -23.1% and a 23.7% success rate. Mamtani covers the Healthcare sector, focusing on stocks such as Lineage Cell Therapeutics, Arrowhead Pharmaceuticals, and Madrigal Pharmaceuticals.

Howard Kim on TipRanks | September 2, 2022

What Is Going on With Vaxart (VXRT) Stock Today?

Vaxart released encouraging results for its oral Covid-19 vaccine, though sentiment for VXRT stock presently remains mixed.

Josh Enomoto on InvestorPlace | September 1, 2022

Vaxart Announces Positive Top-line Phase II Clinical Study Data Demonstrating Safety and Immunogenicity of Its Wuhan S-Only COVID-19 Pill Vaccine Candidate

— Study met primary safety and secondary immunogenicity endpoints — — Boosted serum neutralizing antibodies in both naive and previously mRNA vaccinated subjects — — Elicited cross-reactive mucosal responses in approximately 50% of subjects — — Company to host conference call at 8:30 a.m. ET today — SOUTH SAN FRANCISCO, Calif., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today reported positive top-line data from the first part of a planned two-part Phase II study of its Wuhan

Yahoo | September 1, 2022

Vaxart to Host Conference Call on September 1 at 8:30 AM ET to Discuss Top-line Results from Its Phase II COVID-19 Trial

SOUTH SAN FRANCISCO, Calif., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced it will release top-line data from the first part of its planned two-part COVID-19 Phase II trial of its Wuhan S-only construct before the market open on Thursday, September 1, 2022. The Vaxart senior management team will host a live conference call and webcast beginning at 8:30 a.m. Eastern Time on the same date to review the data and provide a trial update. Analysts and investors can part

Yahoo | August 31, 2022

Read More 'VXRT' Stories Here

VXRT Price Returns

1-mo -30.79%
3-mo -41.87%
6-mo -58.71%
1-year -69.64%
3-year 501.38%
5-year -73.22%
YTD -65.23%
2021 9.81%
2020 1,529.10%
2019 -81.36%
2018 -70.02%
2017 -53.66%

Continue Researching VXRT

Here are a few links from around the web to help you further your research on Vaxart Inc's stock as an investment opportunity:

Vaxart Inc (VXRT) Stock Price | Nasdaq
Vaxart Inc (VXRT) Stock Quote, History and News - Yahoo Finance
Vaxart Inc (VXRT) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6011 seconds.